Showing 15 posts of 54 posts found.


Sanofi abandons MannKind’s failed inhalable insulin

January 6, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Afrezza, Mannkind, Sanofi, insulin

Sanofi is to exit a licensing and co-marketing deal with MannKind for the inhalable insulin Afrezza, after disappointing sales figures …

FDA sign

FDA approves Lilly/Boehringer Lantus biosimilar

December 17, 2015
Medical Communications, Sales and Marketing Basaglar, Boehringer Ingelheim, Eli Lilly, Lantus, Sanofi, abasaglar, biosimilar, diabetes, insulin, lilly

The FDA has approved Eli Lilly and Boehringer Ingelheim’s long-acting insulin Basaglar (insulin glargine injection – a biosimilar to rival Sanofi’s …


Novo Nordisk posts strong nine-month results

October 29, 2015
Sales and Marketing Novo Nordisk, insulin

Novo Nordisk has exceeded market expectations in its nine-month financial results, reporting a 51% increase in operating profit and 33% …

Novo Nordisk building

FDA approves Novo Nordisk’s diabetes drugs

September 28, 2015
Sales and Marketing FDA, Novo Nordisk, Ryzodeg, Tresiba, diabetes, insulin

The FDA has approved two Novo Nordisk drugs, Tresiba and Ryzodeg, for the treatment of type 2 diabetes in adults.The …


Novo Nordisk abandons Victoza submission after mixed T1D results

August 26, 2015
Research and Development Novo Nordisk, Victoza, diabetes, insulin

Novo Nordisk has been forced to scrap plans to expand its licence for Victoza to include adults with type 1 …

Toujeo pen

Sanofi launches new insulin Toujeo in the UK

August 4, 2015
Manufacturing and Production, Sales and Marketing Lantus, Sanofi, biosimilars, diabetes, hypoglycaemia, insulin, toujeo

Sanofi’s new insulin Toujeo is now available for clinicians to prescribe in the UK. The French firm is looking to …


Mixed Phase 3 results for Sanofi and UCB

July 29, 2015
Research and Development LixiLan, Sanofi, UCB, clinical trials, epratuzumab, insulin, insulin glargine, phase III

Two drugs that pharma companies are pinning hopes on for future success have had mixed outcomes in key late-stage clinical …

Novo image

Novo Nordisk opens insulin plant in Russia

April 10, 2015
Manufacturing and Production, Sales and Marketing Novo Nordisk, Russia, diabetes, flexpen, insulin, kaluga, penfill

Denmark’s Novo Nordisk has opened a new manufacturing facility in Russia to produce more of its diabetes offerings in the …

affrezza image

Sanofi’s inhalable insulin goes on sale in US

February 3, 2015
Sales and Marketing Afrezza, FDA, Mannkind, Sanofi, US, apidra, diabetes, insulin, type 1, type 2

Sanofi has launched its inhalable insulin Afrezza in the US to control blood sugar in people with type 1 and …

NICE changes insulin advice in diabetes guidelines

December 12, 2014
Sales and Marketing NHS, NICE, diabetes, health survey, insulin, type 1, type 2

NICE has changed its recommendations on type 1 diabetes in adults and children, and type 2 diabetes in children, to …

afrezza image

Sanofi signs $925 million inhaled insulin deal

August 13, 2014
Sales and Marketing Afrezza, French, Sanofi, diabetes, fad, insulin

Sanofi could pay out as much as $925 million for global rights to the world’s only approved inhaled insulin just …

Lantus image

Insulin blockbusters targeted by biosimilar blitz

February 15, 2013
Research and Development, Sales and Marketing Biocon, Humalog, Mylan, insulin

Mylan and Biocon are the latest companies to announce major new plans to develop and market biosimilars. The firms are …

lilly image

New plant positions Lilly for changing insulin market

November 6, 2012
Manufacturing and Production Boehringer, insulin, lilly

Eli Lilly has unveiled plans for a $140 million expansion of its insulin plant in Indianapolis as it starts to …

Novo confident on ultra-long acting insulin

December 8, 2011
Sales and Marketing Novo Nordisk, diabetes, insulin

Novo Nordisk says a new combination of a long-acting insulin with a short-acting insulin helps patients maintain better control of …

No cancer link with Lantus, says Sanofi

December 7, 2011
Sales and Marketing Cancer, Lantus, Sanofi, diabetes, insulin, safety

Sanofi has presented a new meta-analysis which suggests its insulin blockbuster Lantus does not raise the risk of cancer. A …

Latest content